Scarica l'app Stockscreener
1.51
1.33%
0.01
Beyondspring Inc Borsa (BYSI) Ultime notizie
BeyondSpring (NASDAQ:BYSI) Trading Down 3.8%Here's Why - MarketBeat
BeyondSpring’s 2024 Progress and Strategic Milestones - TipRanks
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline By Investing.com - Investing.com South Africa
BeyondSpring stock hits 52-week low at $1.4 amid sharp decline - Investing.com
BeyondSpring Inc. (BYSI) reports earnings - Quartz
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones - The Manila Times
BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewswire
Just Released: BeyondSpring's Complete 2024 Financial Performance and Cancer Pipeline Updates - Stock Titan
Global Febrile Neutropenia Market Forecast 2025-2034: Analyzing Growth Drivers, Market Share, Segments, And - EIN News
In-Depth Analysis Of The Global Febrile Neutropenia Market Advancements Highlighted by Key Drivers, Trends,... - WhaTech
BeyondSpring's PlinabulinA Pipeline In Itself? - RTTNews
Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
BeyondSpring, Inc. to Host Earnings Call - ACCESS Newswire
Pliant Therapeutics stock tumbles amid IPF trial cancellation - Clinical Trials Arena
BeyondSpring finalizes significant asset sale By Investing.com - Investing.com South Africa
BeyondSpring finalizes significant asset sale - Investing.com India
BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.6%Time to Buy? - MarketBeat
Cancer Vaccines Market on Track for Major Expansion in - One News Page
Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - Citeline News & Insights
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN
BeyondSpring Inc. Enters into Preferred Share Purchase Agreement with SEED Therapeutics Inc. - Defense World
BeyondSpring sells SEED Therapeutics shares for $35.4M - MSN
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - The Manila Times
BeyondSpring sells SEED Therapeutics shares for $35.4M By Investing.com - Investing.com UK
BeyondSpring Announces $35.4 Million Sale of a Portion of - GlobeNewswire
SEED Receives FDA Rare Pediatric Disease and Orphan Drug - GlobeNewswire
BeyondSpring Cashes In $35M Stake as Cancer Drug Shows 89% Disease Control Rate - StockTitan
BeyondSpring (NASDAQ:BYSI) Shares Down 1.4%Here's Why - MarketBeat
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight - The Malaysian Reserve
BeyondSpring Inc. Announces Change in Domestic Filing Status and Disclosure Channels to Disseminate Information - Defense World
BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com
Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight - The Malaysian Reserve
CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight - The Malaysian Reserve
Retail investors reap multibagger gains by betting on these 29 - Oficjalny Portal Gminy Brzesko
BeyondSpring (NASDAQ:BYSI) Shares Up 4.5%Here's Why - MarketBeat
BeyondSpring (NASDAQ:BYSI) Trading 4.5% Higher – Here’s Why - Defense World
Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
Non-small Cell Lung Cancer Treatment Market 2032: Clinical - openPR
2.65%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):